ArticleBritish journal of cancer2020
Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma.
Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Circulating tumor DNA and prognosis in gastric cancer patients undergoing surgery: meta-analysis and trial sequential analysis.Frontiers in oncology · 2026Pooled it
- Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.EBioMedicine · 2024Pooled it
- An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022Pooled it
- Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study.International journal of clinical oncology · 2026Trial
- Perioperative Circulating Tumor DNA in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: Molecular Residual Disease, Recurrence Prediction, and a Trial-Ready Framework for Treatment Adaptation.Journal of gastrointestinal cancer · 2026Review
- Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.Nature reviews. Clinical oncology · 2026Review
- Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Article
- Article
- Review
- Neoadjuvant Chemotherapy for Gastric Cancer: Evolving Approaches and Supporting Evidence.Journal of gastric cancer · 2026Review
- Repeated lymph-node recurrences after radical endoscopic submucosal dissection in a patient of esophageal squamous cell carcinoma, judged as pT1a-LPM: a case report and literature review.Clinical journal of gastroenterology · 2025Review
- Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review.World journal of gastrointestinal oncology · 2025Review
- Comparison of real-time PCR and nCounter NanoString techniques to validate copy number alterations in oral cancer.Scientific reports · 2025Article
- The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine.Cancer research and treatment · 2025Review
- Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions.JCO precision oncology · 2025Article
- Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.Frontiers in oncology · 2025Review
- New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People.Current aging science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGastroesophageal adenocarcinoma (GOA) has poor clinical outcomes and lacks reliable blood markers. Here we present circulating tumour DNA (ctDNA) as an emerging biomarker.
methodsForty patients (17 palliative and 23 curative) were followed by serial plasma monitoring. Primary tumour DNA was analysed by targeted next-generation sequencing to identify somatic single-nucleotide variants (SNVs), and Nanostring nCounter
resultsThirty-five patients (13 palliative, 22 curative) had ≥1 SNVs and/or CNA
conclusionSensitive ctDNA detection allows disease monitoring and prediction of short OS in metastatic patients. Presence of ctDNA postoperatively predicts relapse and defines a 'molecular relapse' before overt clinical disease. This lead time defines a potential therapeutic window for additional anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.